CTS NK-Xpander Medium
產品名稱: CTS NK-Xpander Medium
英文名稱: Gibco CTS NK-Xpander Medium
產品編號: A5019002
產品價格: 0
產品產地: 美國
品牌商標: Gibco
更新時間: null
使用范圍: null
北京百奧創新科技有限公司
- 聯系人 :
- 地址 : 北京市海淀區創客小鎮
- 郵編 :
- 所在區域 : 北京
- 電話 : 133****0421 點擊查看
- 傳真 : 點擊查看
- 郵箱 : customer@bestopbio.com;3007606172@qq.com
Superior expansion potential: CTS NK-Xpander Medium is capable of producing a high yield of hNK cells without the need for feeder cells, providing robust expansion of enriched hNK cells from hPBMCs from qualified donors at day 14 to 15 versus other medium options. Cells maintain CD56+/CD16+/CD3- surface marker expression and demonstrate cytolytic capabilities. Manufactured for cell therapy applications: CTS NK-Xpander Medium is manufactured without cytokines and growth factors to allow flexibility with regard to intended application. The medium does not include human or animal-derived components; however, supplementation with hAB serum is recommended for best results. CTS quality: Gibco CTS products follow USP <1043> 'ancillary materials for cell, gene, and tissue-engineered products' within the responsibilities applicable to a supplier.* Documentation such as specific intended-use statements, full documentation traceability, and convenient access to our Drug Master File (DMF) are available to support your regulatory filing. The products are manufactured at a site that uses methods and controls that conform to cGMP for medical devices, 21 CFR Part 820. Our FDA-registered manufacturing sites are ISO 13485-certified. Closed-system compatibility: CTS NK-Xpander Medium is available in 500-mL-bottle and 5-L-bag formats for convenient process development and closed-system manufacturing scale-up. The 5-L bioprocess container chamber is constructed from Aegis 5-14 film and includes sterile, weldable DEHP-free PVC tubing with Luer lock and C-Flex tubing with MPC quick connector providing versatile connection options for your manufacturing process, including compatibility with the CTS Rotea Counterflow Centrifugation System. *Other aspects of USP <1043> will be the responsibility of the end-user to assess. Thermo Fisher Scientific cannot fulfill USP <1043> in regards to application and therapy-specific aspects (e.g., residual assessment and removal of the AM).
